Microrna-21, Mismatch Repair, and Colorectal Cancer

The Need: Colorectal cancer (CRC) is a significant health concern, with a high incidence rate and limited treatment options, particularly regarding resistance to standard chemotherapy like 5-fluorouracil (5-FU). The management of CRC patients is complicated by the frequent occurrence of primary or acquired resistance to pyrimidine analog treatments. To improve patient outcomes, there is an urgent need for a better understanding of the underlying resistance mechanisms and the development of more effective therapies.

The Technology: The presented technology is a groundbreaking innovation in the field of molecular biology, specifically targeting cancer-related applications. It revolves around miR-21, a microRNA known to be over-expressed in various malignancies, including colorectal cancer. This technology involves the diagnostics, therapeutics, and prognostics of miR-21-associated colorectal cancers by utilizing an anti-sense miRNA approach to regulate the core mismatch repair (MMR) recognition proteins, hMSH2 and hMSH6. By targeting and down-regulating miR-21, this technology aims to enhance the therapeutic efficacy of 5-FU and improve outcomes for CRC patients.

Commercial Applications:

  1. Diagnostic Tool for CRC: The technology can be used as a diagnostic tool to identify miR-21 over-expression in blood and stool samples, aiding in early detection and personalized treatment plans for colorectal cancer patients.
  2. Therapeutic Agent: The technology's antisense miR-21 compositions can be utilized as a novel therapeutic agent to sensitize 5-FU-resistant colorectal cancer cells, overcoming drug resistance and improving treatment effectiveness.
  3. Prognostic Indicator: By assessing miR-21 expression levels and its association with hMSH2 down-regulation, this technology can serve as a prognostic indicator to predict therapeutic efficacy and clinical outcomes in colorectal cancer patients.


  1. Enhanced Treatment Efficacy: Targeting miR-21 and hMSH2 through the antisense miRNA approach improves the sensitivity of 5-FU treatment, leading to enhanced therapeutic efficacy in colorectal cancer patients.
  2. Personalized Medicine: By identifying miR-21 expression levels, clinicians can tailor treatment strategies, ensuring a more personalized and effective approach for each CRC patient.
  3. Early Detection: The diagnostic application of this technology enables early detection of colorectal cancer by identifying miR-21 over-expression, facilitating timely interventions and potentially improving patient outcomes.
  4. Improved Prognostication: The technology's ability to predict therapeutic efficacy and clinical outcomes based on miR-21 and hMSH2 status helps clinicians make more informed decisions and optimize treatment plans for CRC patients.
  5. Novel Research Tool: Researchers can use this technology as a valuable tool to explore and study miR-21-associated colorectal cancers, advancing our understanding of the disease and potential therapeutic targets.

In conclusion, the miR-21-associated colorectal cancer technology represents a significant advancement in molecular biology with wide-ranging applications in diagnostics, therapeutics, and prognostics. Its potential to enhance treatment efficacy, enable personalized medicine, and aid early detection make it a promising solution in the fight against colorectal cancer.


Patent # Title Country
8946187 Materials and Methods Related to MicroRNA-21 Mismatch Repair and Colorectal Cancer United States of America
9394543 Materials and Methods Related to MicroRNA-21 Mismatch Repair and Colorectal Cancer United States of America

Loading icon